News

April 13, 2018

Bright Pink Creates Online Courses on Preventing Ovarian and Breast Cancer

News

The U.S. women’s health organization Bright Pink has created online courses designed to improve care providers’ ability to manage their patients’ risk of developing ovarian and breast cancer. The courses consist of ... Read more

April 11, 2018April 11, 2018

First Patient Treated in Test of OLT38, a Dye to Detect Ovarian Cancer Tissue During Surgery

News

A Phase 3 clinical trial testing a special dye that “lights up” ovarian tumor tissue during surgery has treated its first participant, On Target Laboratories announced. The dye, called OTL38, is ... Read more

April 9, 2018

Zejula-Keytruda Combo Shows Promise in Certain Ovarian Cancer Patients in Clinical Trial

News

A combination of Zejula (niraparib) and Keytruda (pembrolizumab) reduced tumor size in one out of four difficult-to-treat ovarian cancer patients, Tesaro‘s Phase 1/2 trial revealed. The 25% response rate seen in ... Read more

April 6, 2018

Bedside Chart Improves Cancer Patients’ Pain Management, Study Shows

News

A simple bedside chart for assessing and managing pain reduced hospitalized cancer patients’ pain without increasing their use of opioids, a large British study showed. Its findings suggested that systematic ... Read more

April 4, 2018

FATE-NK100 Shows Signs of Tumor Reduction in First Ovarian Cancer Patients in Phase 1 Trial

News

FATE-NK100, a natural killer cell immunotherapy, induced stable disease in one of the first two heavily treated ovarian cancer patients in a Phase 1 trial. No dose-limiting toxicities have been reported so ... Read more

April 2, 2018

Personalized Immunotherapy May Be Effective Ovarian Cancer Treatment, Study Finds

News

A new method that identifies and expands T-cells with high tumor-killing activity is a promising approach against ovarian cancer, a study shows. Findings could be used to develop a personalized, cell-based ... Read more

March 28, 2018

EU’s CHMP Supports Rubraca’s Approval for Advanced, Recurrent Ovarian Cancer

News

Rubraca (rucaparib) is a step closer to availability in Europe for ovarian cancer patients with relapsed or progressive disease. The E.U.’s Committee for Medicinal Products for Human Use (CHMP) recently ... Read more

March 26, 2018

Phase 1 Trial Finds TPIV200 Is Safe, Delays Recurrence in Ovarian, Breast Cancer

News

An investigational vaccine called TPIV200 was found to be safe and generated strong T-cell immunity against tumor cells, significantly delaying recurrence in breast and ovarian cancer patients who had achieved complete ... Read more

March 23, 2018March 23, 2018

Cotinga Looks to Expand COTI-2 Trial to Include Other Therapy Combos

News

Cotinga Pharmaceuticals is seeking approval from the U.S. Food and Drug Administration (FDA) to expand its ongoing Phase 1 trial of COTI-2 to include combination therapies and a broader spectrum of ... Read more

March 21, 2018

Genetic Testing Helps Identify Ovarian Cancer Patients with BRCA Mutations, UK Study Finds

News

Genetic testing as part of routine cancer care, an approach called mainstreamed genetic testing, or MGT, is a feasible way to test BRCA mutations in ovarian cancer patients, a new U.K. study ... Read more